Intervening in aging and related diseases with gene therapy techniques Authors: Mengmeng Jiang, Jing Qu, Moshi Song, Guang-Hui Liu Published: 2026 ABSTRACT SummaryAging is the primary risk factor for most chronic diseases, and the global rise in aging populations presents an escalating challenge due to functional decline and multimorbidity. Gene therapy provides a versatile framework for modulating aging-regulatory pathways, such as epigenetic regulation, telomere maintenance, and stress-response networks, with the potential to reshape aging trajectories. In this review, we provide an in-depth synthesis of the genetic and epigenetic determinants of aging and highlight advances in gene-based approaches, including genome editing, RNA modulation, and epigenetic reprogramming, all of which hold promise as geroprotective strategies. Furthermore, we discuss mechanistic insights, safety considerations, and translational frameworks, offering a broad, conceptually grounded overview to guide the development of aging gene interventions aimed at improving the healthspan and reducing age-associated dysfunction.Keywords: aging, age-associated diseases, gene therapy, intervention Introduction Aging is a systemic, multifactorial process marked by progressive decline in physiological integrity and resilience, increasing vulnerability to disease and death.1 Global life expectancy in 2021 averaged 71.7. years, yet healthy life expectancy, years lived free of disease or disability, was only 62.2, highlighting a substantial period of life spent in poor health.2 Aging is the primary risk factor for most chronic diseases and underlies widespread multimorbidity, complicating treatment and healthcare delivery.3 Addressing aging itself, rather than individual diseases, is therefore essential for extending healthspan. Over the past decades, a diverse range of geroprotective interventions has been explored, spanning lifestyle modifications, pharmacological agents, regenerative medicine, and gene-based therapies. Lifestyle interventions, such as exercise and dietary regulation, remain the cornerstone of healthy aging, with detectable clinical and epidemiological evidence supporting their ability to enhance metabolic, cardiovascular, and cognitive health.4 Pharmacological strategies, including metformin, vitamin C, and betaine contribute to an expanding pharmacological toolkit aimed at mitigating aging-associated decline.5,6,7 Regenerative strategies, including stem cell replacement and epigenetic reprogramming, show potential to improve tissue homeostatic capacity across various systems, while senolytic agents that selectively eliminate senescent cells promise to delay tissue degeneration and improve health span.8,9 Within this landscape, gene-based therapies have emerged as a promising approach due to their ability to target fundamental molecular pathways that drive aging. Unlike non-genetic interventions, gene therapies offer the potential for durable benefits by programmably modulating key aging-associated mechanisms at the genetic and epigenetic levels. However, despite these advantages, gene therapies still face substantial challenges related to delivery efficiency, safety, cost, ethical considerations, and long-term outcomes. When integrated with non-genetic interventions, these gene-based strategies represent a versatile, complementary approach for extending healthspan and mitigating aging-associated decline. This review summarizes recent advancements in the genetic regulation of aging and gene-based interventions, comparing the advantages and limitations of various approaches. It highlights key genetic targets and therapeutic methods, focusing on the potential of gene-based strategies to programmably target fundamental aging mechanisms. The review also addresses challenges such as delivery efficiency, safety, and ethical concerns, while emphasizing the long-term outcomes of these therapies. Ultimately, it aims to provide a theoretical foundation and technical insights to support future precision geroprotective research and clinical translation. Genetic determinants of aging as targets for translational gene therapy Aging is defined as a progressive decline in organismal function and is characterized by 14 hallmarks.10 Emerging evidence positions aging not merely as a consequence of stochastic molecular damage but as a process shaped by genetic regulation. This regulation involves pro-aging (“gerogenes”) and geroprotective genes, whose effects are tissue, context, dose, and stage dependent. Their impact is not strictly binary: modulation can be beneficial or detrimental depending on expression, cellular context, and timing. Here, we focus on “aging-targeted” gene therapies, interventions directed at genes whose expression or function changes during chronological aging and whose experimental modulation counteracts one or more aging hallmarks, extending healthspan or lifespan in preclinical models. We summarize recent progress in identifying gerogenes and geroprotective genes and discuss their translational potential in aging intervention (Figure 1). Overview of aging hallmarks and regulatory genes This circular schematic illustrates the 14 interrelated hallmarks of aging and representative aging-regulated genes associated with each process. Together, these modules highlight the multilayered organization of aging biology and nominate potential genetic entry points for geroprotective intervention. Figure created using BioRender. Genomic instability Genomic instability is a fundamental hallmark of aging, reflecting the progressive erosion of mechanisms that safeguard genome integrity. With age, there is a cumulative burden of DNA damage, chromosomal aberrations, telomere shortening, and increased somatic mutations, all of which contribute to cellular dysfunction. In murine models, compound heterozygosity of BRCA1 and p53 results in developmental delay and progeroid phenotypes,11 while in humans, BRCA1 genotypes have been associated withexceptional longevity12 Mutations in RecQ family helicases, including WRN, BLM, and RECQ4, cause rare progeroid syndromes characterized by genomic instability and heterochromatin disorganization. The integrity of nuclear architecture is equally crucial. The nuclear lamina, composed of proteins such as LMNA, BANF1/BAF, and lamin B1, provides structural support and regulates chromatin organization and gene expression.13 De novo heterozygous mutations in LMNA cause Hutchinson-Gilford progeria syndrome (HGPS), whereas homozygous mutations in BANF1 underlie Néstor-Guillermo progeria syndrome, highlighting the central role of nuclear envelope integrity in progeroid aging.14,15 Progerin suppression with lamin A restoration rescues major vascular defects in HGPS mouse models, while adeno-associated virus (AAV)-delivered CRISPR-Cas9-mediated lamin A/progerin reduction extends health and lifespan in HGPS mice.16 Telomere attrition Telomere shortening is a hallmark of cellular aging, reflecting the progressive loss of telomeric DNA with each round of cell division due to the end-replication problem. Core components such as TERT (telomerase reverse transcriptase) and telomerase RNA template (TERC) are critical for telomere maintenance. In Terc−/− mice, successive generations show progressive telomere shortening, chromosomal end-to-end fusions, stem cell dysfunction, and reduced lifespan.17 Conversely, transgenic mice with ubiquitous Tert expression exhibit elevated telomerase activity, longer telomeres, enhanced tissue repair capacity, and a ∼16% increase in median lifespan, notably without a reported increase in cancer incidence.18 Telomerase activation has been explored as a gene-based strategy for telomere maintenance, but its clinical translation remains preliminary and controversial. AAV-hTERT has been registered in early-phase studies for aging-related indications and Alzheimer’s disease (AD), primarily to assess safety and tolerability rather than efficacy.19 Key unresolved issues include oncogenic risk, clonal expansion, tissue specificity, long-term durability, and the regulatory validity of aging as a therapeutic indication. Epigenetic alterations Epigenetic instability is a hallmark of aging, involving changes in DNA methylation, histone modifications, chromatin structure, RNA modifications, and epigenetic regulators. DNA methylation alterations are most prominent and form the basis of “epigenetic clocks,” widely used as biomarkers of human biological age.20 This underscores the advantage of emerging epigenetic editing tools (discussed later), which provide locus-specific control, offering enhanced precision in targeting aging-associated mechanisms. Sirtuins, a family of NAD+-dependent deacetylases, exhibit progressive declines in both expression and enzymatic activity with age, thereby contributing to several epigenetic and metabolic hallmarks of aging across diverse species.21 Their effects are highly tissue and context dependent. For example, SIRT1/Sir2 overexpression extends lifespan in yeast and Drosophila,22,23 but systemic SIRT1 overexpression in mice improves metabolic phenotypes without extending lifespan,24 whereas brain-specific SIRT1 overexpression promotes longevity.25 SIRT6 overexpression extends lifespan in male mice,26 while SIRT7 and SIRT2 have been implicated in vascular and cardiac aging, respectively.27,28 Beyond sirtuins, several chromatin regulators show age-associated dysregulation and functional relevance. CRISPRa-mediated activation of SOX5 restores H3K27ac/H3K4me1 enhancer activity and alleviates cellular senescence phenotypes,29 KAT7 depletion delays hepatocyte senescence and extends lifespan in progeroid mice by lowering H3K14 acetylation,30 and TOP2B/Top2 reduction has been reported to improve selected aging-associated phenotypes across species.31 Together, these findings highlight epigenetic regulators as promising but context-dependent targets for gene-based aging interventions. Loss of proteostasis Loss of proteostasis represents a central hallmark of aging, as the coordinated systems governing protein synthesis, folding, and degradation progressively decline with age. This erosion of quality-control capacity leads to the accumulation of misfolded and aggregated proteins, thereby compromising cellular function across tissues. Post-transcriptional and translational regulation also undergo systemic remodeling with age. In aged mice, ribosomal protein mRNAs show reduced ribosome occupancy across tissues, while activation of 4E-BP1 preserves muscle metabolism and prevents sarcopenia.32 Increased eIF2α phosphorylation lowers global translation but enhances autophagy-related mRNA translation, extending cellular lifespan.33 A recent transcriptomic analysis of long-lived individuals identified the transcription factor ETS1 as a negative regulator of ribosomal protein genes; ETS1 suppression lowers ribosome biogenesis and alleviates cellular senescence, suggesting that reduced translational load may contribute to healthy aging.34 Chaperone-mediated autophagy (CMA), a selective degradation route essential for proteostasis, becomes less efficient with age. Genetic restoration of LAMP2A, the rate-limiting component of CMA, in old mice partially rescues T cell function and attenuates immunosenescence, underscoring the therapeutic potential of maintaining CMA capacity.35 Disabled autophagy Autophagic decline is a conserved hallmark of aging, observed across species and tissues.36 Aging is characterized by reduced autophagic flux, leading to the accumulation of damaged proteins and organelles, which contributes to age-associated diseases such as neurodegeneration and cardiometabolic disorders. Key autophagy genes, including ATG2, ATG5, ATG7, ATG8A, and BECN1, show progressive downregulation with age, underscoring their essential role in maintaining cellular homeostasis.37 In Caenorhabditis elegans, intact autophagy gene expression is required for lifespan extension in insulin/IGF-1 signaling mutants. The transcription factor HLH30 (TFEB ortholog) acts as a master regulator of autophagy and lysosomal genes; its overexpression enhances autophagic flux and extends lifespan.38 In Drosophila, overexpressing Atg1 or Atg8a similarly promotes systemic autophagy and longevity.39,40 In mammals, particularly mice, aging is associated with reduced expression of autophagy-related genes and increased mechanistic target of rapamycin (mTOR) activity. Notably, ubiquitous overexpression of Atg5 in transgenic mice enhances autophagy, improves metabolic health (leanness and insulin sensitivity), and extends median lifespan by ∼17%.41 In hematopoietic stem cells, autophagy preserves regenerative function via SIRT3-mediated oxidative stress reduction, while FOXO3 activation delays senescence by modulating autophagy pathways.42 Deregulated nutrient sensing Aberrant nutrient sensing is increasingly recognized as a fundamental driver of aging across species. Dysregulation in the metabolism of carbohydrates, lipids, and amino acids often leads to the accumulation of intermediate metabolites, triggering cellular dysfunction and accelerating the aging process.1,43 During aging, a progressive decline in growth hormone (GH)/insulin-like growth factor 1 (IGF-1) levels leads to reduced activity of downstream effectors, including FOXO transcription factors, AKT, IGF1R, and MTOR, all of which play pivotal roles in longevity regulation.44 Drosophila fat-body dFOXO overexpression extends lifespan, and Foxo3 knockout eliminates the lifespan-extending effect of dietary restriction in mice.45,46 The anaplastic lymphoma kinase (Alk) pathway has also been implicated in metabolic regulation of aging. In Drosophila, genetic or pharmacological inhibition of Alk extends healthy lifespan, suggesting that neuronal receptor tyrosine kinase signaling may influence organismal aging.47 Members of the nuclear receptor family, particularly peroxisome proliferator-activated receptors (PPARs), also play crucial roles in the regulation of lipid and glucose metabolism and inflammatory responses. For example, genetic reduction of Pparg shortens lifespan in mice, supporting Pparg as a longevity-associated metabolic regulator.48 Lipoproteins and their receptors further modulate systemic aging. Apolipoprotein E (APOE) deficiency promotes atherosclerosis and neurodegeneration, contributing to reduced lifespan.49 Oxidative stress and mitochondrial dysfunction Aging-associated mitochondrial decline, characterized by mtDNA mutations, impaired respiratory complexes, reduced turnover, and disrupted dynamics, leads to bioenergetic failure and excessive reactive oxygen species (ROS) production.1,50 This promotes chronic inflammation, apoptosis, and tissue degeneration, key hallmarks of aging. POLG mutations impair mtDNA replication and cause multisystem mitochondrial disease. Importantly, Polg mutator mice develop progressive progeroid phenotypes across multiple tissues, making them a widely used model linking mtDNA instability to organismal aging.51 Beyond genome-maintenance genes, reductions in key antioxidant regulators exacerbate aging. Mitochondrial SOD2 (Mn-SOD) is essential for superoxide detoxification. Its overexpression in myoblasts preserves mtDNA copy number and mitochondrial function with age,52 whereas genetic deletion of Sod2 in mice causes premature death, accompanied by diverse metabolic and mitochondrial defects as well as severe tissue pathologies, including a lethal spongiform neurodegenerative disorder.53 Components of the mitochondrial unfolded protein response (UPRmt), such as ATFS-1 and its downstream effectors, further buffer age-associated mitochondrial stress; mild UPRmt induction has been shown to extend lifespan in model organisms.54 Cellular senescence Cellular senescence is a key driver of aging and age-associated disease, marked by stable cell-cycle arrest, senescence-associated secretory phenotype (SASP) activation, and increased expression of CDKN1A (p21) and CDKN2A (p16). Transgene-mediated inducible elimination of p16Ink4a-positive senescent cells in animal models alleviates multiple aging-associated phenotypes, supporting senescent cells as actionable targets for gene-based intervention.55 However, p16 and p21 are also critical tumor suppressors, and chronic or systemic inhibition of these pathways may increase oncogenic risk.56,57 Thus, senescence-targeted gene therapies should prioritize intermittent, cell-type-specific, and context-dependent strategies, such as selective senescent-cell elimination or transient SASP modulation, to reduce tissue dysfunction while preserving tumor surveillance.58 Extracellular matrix alterations The extracellular matrix (ECM), composed primarily of collagen, elastin, and hyaluronic acid, is essential for maintaining tissue structural integrity and regulating cellular functions. With aging, the ECM progressively stiffens and loses viscoelasticity, leading to disrupted tissue architecture, mitochondrial dysfunction, stem cell exhaustion, and chronic inflammation, thereby promoting systemic aging.1 Hyaluronan synthase 2 (Has2) enhances hyaluronic acid synthesis, with increased Has2 activity shown to extend murine lifespan.59 In the aging brain, mechanosensitive ion channel PIEZO1 is activated, and its inhibition restores oligodendrocyte progenitor cell regenerative capacity.60 ECM glycation can influence brain aging through epigenetic mechanisms involving KMT2A, thereby promoting neuroinflammation and neurodegeneration in an aged neurovascular model.61 Collectively, the ECM functions not only as a mechanical scaffold but also as a dynamic signaling platform regulated by genes such as YAP/TAZ, LOX, HAS2, and PIEZO1. These factors critically influence ECM mechanical properties and cellular crosstalk, driving the aging process and presenting promising targets for geroprotective interventions. Stem cell exhaustion Tissue regenerative capacity markedly declines with age, representing a key hallmark of aging. Adult stem cells are essential for maintaining tissue homeostasis and repairing damage, yet their number and function progressively deteriorate during aging, characterized by cell-cycle arrest, impaired differentiation, and increased senescence, ultimately leading to compromised tissue repair and organ dysfunction.62 Regeneration depends on injury-induced dedifferentiation and cellular plasticity, processes closely regulated by pathways implicated in stem cell aging.62 The mTOR pathway, a central regulator of cell growth and metabolism, modulates lifespan. Hypomorphic mutations that reduce mTOR activity can extend mouse lifespan by up to 20% without adverse metabolic effects.63 Cellular reprogramming has emerged as a promising avenue to attenuate aging by resetting aging markers, including p16 levels, telomere length, and DNA methylation. Intermittent induction of Yamanaka factors OSKM (Oct4, Sox2, Klf4, and c-Myc) in progeroid mice reverses premature aging and extends lifespan without increasing tumorigenesis.64 Furthermore, cyclic expression of FOXM1 prolongs lifespan and enhances regeneration in both progeroid and normal mice.65 Altered intercellular communication Intercellular communication is essential for tissue homeostasis but becomes progressively dysregulated during aging. Age-associated changes include enhanced inflammatory signaling, diminished regenerative and repair cues, altered hormonal regulation, impaired cell junctions, and disrupted tissue microenvironments.66,67,68,69 These changes compromise coordinated tissue function and contribute to systemic functional decline. Although inflammaging and SASP-driven NF-κB activation are important components of altered communication, broad suppression of NF-κB may impair immune function and increase oncogenic risk, highlighting the need for carefully balanced and context-specific modulation.70,71 In parallel, aging is associated with reduced regenerative signaling, such as decreased HGF expression in aged liver, dysregulated TIMP2 signaling linked to cognitive decline, and altered activity of systemic growth factors including VEGF, which influence fibrosis, vascular function, and tissue repair.72,73,74,75 Notably, genetic augmentation of VEGF signaling in aged mice, using a VEGF gain-of-function approach to counteract age-associated VEGF signaling insufficiency, prevented capillary rarefaction, improved tissue perfusion and liver-muscle function, attenuated systemic aging phenotypes, and extended lifespan by approximately 40%.75 Chronic inflammation Aging is accompanied by immunosenescence, impaired clearance of damaged cells, and accumulation of senescent cells, whose SASP factors, including IL-6, TNF-α, type I interferons, and chemokines, establish a persistent inflammatory state known as inflammaging70 Multiple inflammatory pathways have been functionally linked to aging phenotypes and may serve as targets for gene-based modulation. IL-1 and type I interferon signaling contribute to hematopoietic niche inflammation and abnormal monocyte accumulation in aged tissues.76,77 Recent studies further identify IgG and Williams syndrome transcription factor (WSTF) as regulators of systemic and cellular inflammatory aging, with antisense-based IgG suppression or WSTF restoration attenuating aging-related inflammatory phenotypes.78,79,80 These findings suggest that inflammaging could be targeted by RNA modulation, CRISPR-based transcriptional control, or cell-type-specific gene editing. Macrophages, monocytes, and hematopoietic progenitors are particularly relevant targets, as CRISPR screens have identified regulators of NF-κB signaling, inflammatory senescence, and cytokine feedback loops.81,82 However, inflammatory pathways also preserve host defense and tissue repair. Future gene-based interventions should prioritize context-dependent and cell-type-specific modulation rather than broad cytokine blockade, aiming to restore immune homeostasis without compromising protective immunity. Dysbiosis Dysbiosis, defined by age-associated disruption of microbiota composition and host-microbe homeostasis, is increasingly recognized as an integrative hallmark of aging. It can impair epithelial barrier function, amplify inflammation, alter microbial metabolites, and accelerate tissue dysfunction. Importantly, dysbiosis is genetically modifiable in model organisms. In Drosophila, intestinal epithelial restoration of peptidoglycan recognition protein SC2 (PGRP-SC2) prevents age-associated dysbiosis, preserves gut homeostasis, and extends lifespan83; similarly, regional inhibition of intestinal JAK/STAT signaling limits dysbiosis, epithelial decline, and lifespan shortening.84 In mammals, Lyz1 deficiency induces gut dysbiosis and promotes vascular inflammatory aging, whereas lysozyme supplementation restores microbial balance and attenuates vascular aging phenotypes.85 Beyond host genes, microbial genetic composition can also influence longevity, as E. coli mutant screens in C. elegans identified bacterial gene deletions that extend host lifespan.86 These findings suggest that dysbiosis may be targeted through host epithelial immune regulators, antimicrobial programs, barrier-maintenance pathways, or engineered microbial systems, although mammalian translation remains immature. Psychosocial isolation Psychosocial isolation has recently been incorporated into the expanded framework of aging hallmarks, but it should not be viewed as a conventional gene therapy target because it represents a supracellular and behavioral determinant of aging.10 Instead, gene-based intervention may act on downstream neurotrophic and stress-response pathways that mediate its biological impact. Notably, aging and social isolation have both been linked to reduced brain-derived neurotrophic factor (BDNF) expression in reward-related brain circuits, while hypothalamic AAV-mediated BDNF gene transfer promotes healthier aging phenotypes in aged mice.87 These findings suggest that psychosocial isolation may be indirectly addressed through genetic modulation of neurotrophic resilience pathways, although behavioral and social interventions remain essential. Clinical gene therapy trials targeting age-associated disorders Aging is a fundamental risk factor for a wide range of chronic diseases, including neurodegenerative and metabolic conditions, which contribute to the growing global healthcare burden. In response, aging-focused gene therapies have emerged as a promising avenue for targeted interventions. From early conceptual models to preclinical studies and initial clinical trials, these therapies have evolved to address various age-associated diseases through diverse targets, strategies, and delivery systems. This section summarizes the latest clinical trial progress in aging-associated chronic diseases (Table S1), highlighting key therapeutic approaches, reported outcomes, and remaining translational challenges (Figure 2). Gene interventions for age-associated diseases Schematic overview of representative gene interventions that have been evaluated in preclinical or clinical studies for age-associated diseases. Therapeutic genes are organized by target disease: Alzheimer’s disease (AD), age-related macular degeneration (AMD), Parkinson’s disease (PD), and sarcopenia. AAV, adeno-associated virus; LV, lentiviral vector; P, preclinical; C, clinical trial; CFI, complement factor I; TREM2, triggering receptor expressed on myeloid cells 2; IGF2, insulin-like growth factor 2; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; SGα, sarcoglycan α. Figure created using BioRender. Alzheimer’s disease AD is the most prevalent neurodegenerative disorder in the elderly, characterized by progressive cognitive decline and memory loss.88 Gene therapy is being explored as an approach to address the multifactorial nature of AD. Strategies targeting neprilysin overexpression or enhancing CYP46A1 activity have been shown to reduce amyloid-β (Aβ) accumulation.89,90 Similarly, silencing GSK3β or promoting tau degradation pathways can mitigate neurofibrillary tangle formation. Moreover, AAV-mediated delivery of neurotrophic factors such as BDNF and insulin-like growth factor 2 (IGF2) has demonstrated the potential to restore synaptic plasticity, improve cognitive function, and enhance neuronal survival in rodent and non-human primate models.91,92,93 Early open-label phase 1/2 data (LX1001, NCT03634007) suggest increased APOE2 expression and exploratory reductions in cerebrospinal fluid (CSF) tau biomarkers.91 Several AD-related gene therapies are in early-phase clinical testing. LX1001 is being evaluated in an open-label phase 1/2 study, while AAV2-BDNF is being assessed in an open-label phase 1 study for early AD/mild cognitive impairment (MCI). Microglial-targeted genetic interventions offer a complementary therapeutic avenue. Microglia are central to Aβ clearance, neuroinflammation, and synaptic remodeling.94 Mechanistically distinct strategies have been explored: conditional CSF1R deletion primarily depletes microglia, as CSF1R signaling is essential for microglial survival, which indirectly reduces plaque burden by transiently removing dysfunctional microglia.95 In contrast, modulation of microglial activation or polarization, such as triggering receptor expressed on myeloid cells like 2 (TREML2) manipulation or antisense oligonucleotide (ASO)-mediated knockdown of triggering receptor expressed on myeloid cells 2 (TREM2)/APOE, reprograms surviving microglia without depleting them, enhancing phagocytic capacity, plaque-associated clustering, and anti-inflammatory responses.96 Despite these advances, delivering genetic payloads specifically to microglia in humans remains challenging, and the dual neuroprotective and neurotoxic roles of microglia across disease stages necessitate precise, context-dependent interventions. Parkinson’s disease Parkinson’s disease (PD) is a common neurodegenerative disorder primarily affecting older adults, ranking as the second most prevalent neurodegenerative condition after AD in individuals over 65.97 Aging amplifies pathogenic processes, including α-synuclein misfolding, mitochondrial dysfunction, impaired lysosomal degradation, and redox imbalance, many of which are genetically determined.98 To enable controlled gene expression, lentiviral vectors (LVs) encoding glial cell line-derived neurotrophic factor (GDNF) fused to destabilizing domains were developed; trimethoprim administration allowed temporal regulation, resulting in neuroprotection and motor improvement in rodent PD models.99 Gene therapy clinical trials primarily utilize viral vectors (AAV and LV) to enhance neurotrophic support and dopamine synthesis, and modulate pathogenic genes. AAV2-mediated delivery of glutamic acid decarboxylase (GAD) to the subthalamic nucleus (NCT00643890) yielded modest motor benefits but limited overall efficacy. The Cere-120 trial delivering neurturin (NRTN) to the putamen demonstrated detectable local transgene expression but insufficient anterograde transport from the substantia nigra to the putamen, which likely contributed to the limited neuroprotective effects.100 ProSavin, a LV encoding TH, AADC, and GCH1 showed safety and dose-dependent motor improvements in a phase 1/2 open-label study.101 AAV-mediated AADC monotherapy (e.g., VY-AADC01, NCT03065192) produced sustained transgene expression and dose-related clinical improvements including motor function and reduced medication at 12 months.102 Gene therapy targeting GBA1 mutations, a major genetic risk factor for PD, is progressing toward clinical application. CAP-003 is an intravenously delivered gene therapy based on an engineered AAV capsid currently in clinical development for GBA1-associated PD, while ongoing trials such as PROPEL (NCT04127578) are assessing immunogenicity as a key safety endpoint for its GBA1-targeted approach. In an open-label phase 1b study, AAV2-GDNF/AB-1005 was reported to be well tolerated and associated with numerical stability or improvement in motor assessments, supporting Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation but requiring controlled validation. BIIB094/ION859, an intrathecal LRRK2-targeting ASO, showed target engagement and a generally acceptable short-term safety/tolerability profile in a phase 1 study. A critical lesson from past PD gene therapy trials (e.g., Cere-120) is the importance of anatomical targeting and coverage. Future efforts must ensure adequate delivery and biodistribution of the therapeutic agent throughout the complex brain networks affected in PD. Age-related macular degeneration Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, and its prevalence is increasing with population aging, creating a major public health burden.103 Genetic and mechanistic studies have identified several AMD-relevant pathways that may be amenable to gene-based strategies. First, complement dysregulation, particularly the CFH Y402H risk variant, impairs complement regulation and increases the susceptibility of retinal pigment epithelium (RPE) to inflammatory and oxidative injury.104 Second, risk variants at the ARMS2/HTRA1 locus are associated with altered ECM remodeling, RPE dysfunction, apoptosis, and inflammation.105 Third, epitranscriptomic regulation has recently been implicated in AMD, with ALKBH3-mediated RNA demethylation linked to increased VEGF translation and aberrant angiogenesis.106 Fourth, mitochondrial dysfunction promotes ROS accumulation and NLRP3 inflammasome activation, leading to IL-1β and IL-18 release and further RPE damage.107 These pathways offer diverse targets for gene-based strategies. Preclinical complement-modulating gene therapies have provided proof-of-concept support for AMD intervention. AAV-CFI delivery achieves functional CFI expression in human cells and mouse retina, whereas AAV-mediated soluble CD59 reduces membrane attack complex formation and attenuates laser-induced choroidal neovascularization in mice.108,109 By contrast, CRISPR-Cas9 editing of the AMD-associated ARMS2/HTRA1 variant rs10490924 remains primarily a disease-modeling and genetic proof-of-concept strategy in human induced pluripotent stem cell (iPSC)-derived retinal/RPE cells, linking this allele to oxidative-stress susceptibility.110 Sarcopenia Sarcopenia, defined by age-associated loss of muscle mass and function, has been the focus of emerging gene therapy approaches. In preclinical models, AAV9-SaCas9-mediated myostatin disruption enhances muscle fiber number and size, reduces expression of atrophy-related ubiquitin ligases, and promotes satellite cell activation, suggesting potential therapeutic utility for sarcopenia phenotypes.111 Similarly, AAV-mediated overexpression of IGF-1 in adult skeletal muscle prevents age-associated decline in strength and fiber composition by promoting satellite-cell-mediated regeneration.112 In addition, AAV1.NT-3 gene therapy in naturally aged mice improves in vivo muscle physiology, neuromuscular junction (NMJ) connectivity, and myelination, implicating combined trophic and structural mechanisms in ameliorating age-associated muscle decline.113 Genetic enhancement of NMJ stability via AAV9 mediated sarcoglycan α (SGα) expression stabilizes low-density lipoprotein receptor-related protein 4 (LRP4)-muscle-specific kinase (MuSK) signaling and mitigates NMJ fragmentation and denervation in aged mouse muscle, thereby improving neuromuscular transmission and muscle contractility; such interventions address critical components of age-associated muscle dysfunction typical of sarcopenia but have not yet been translated into frailty-specific clinical studies.114 Although gene therapy strategies show promise in preclinical sarcopenia models, major translational challenges include immune responses to viral vectors, regulation of gene dosage, and demonstration of long-term safety and functional benefits in humans. Integrated approaches combining gene therapy with exercise and nutrition remain a key area for future clinical trials. Aging-regulatory pathways Gene therapy, first proposed in the 1960s, entered clinical practice in 1990 when W. French Anderson’s team delivered the adenosine deaminase (ADA) gene to T cells of children with ADA-deficient severe combined immunodeficiency (ADA-SCID), demonstrating its potential for complex diseases.115 Since then, DNA- and RNA-based strategies, including genome and transcriptome editing, transcriptional modulation, and gene-enhanced cell therapies, have rapidly evolved. In aging research, the seminal 1988 discovery that the age-1 mutation extends Caenorhabditis elegans lifespan by 40%–60%116 provided the first direct evidence that specific genes can modulate aging, laying the foundation for modern genetic interventions targeting longevity (Figure 3). Gene therapy for aging and age-associated diseases This diagram categorizes gene therapy approaches into DNA-based and RNA-based methods, highlighting their applications in modulating aging-associated processes. CRISPR, clustered regularly interspaced short palindromic repeats; Cas9, CRISPR-associated protein 9; TALENs, transcription activator-like effector nucleases; ZFNs, zinc finger nucleases; CRISPRi/a, CRISPR interference/activation; siRNA, small interfering RNA; shRNA, short hairpin RNA; ASO, antisense oligonucleotide; CRISPR-Cas13d, CRISPR-associated protein 13d; AAV, adeno-associated virus; AdV, adenoviral vector; LV,lentiviral vector; RV, retroviral vector; LNP, lipid nanoparticles; RISC, RNA-induced silencing complex; PAM, protospacer adjacent motif; TSS, transcription start site. Figure created using BioRender. DNA-based gene strategies for aging intervention 1.Gene editing Gene editing Gene editing has emerged as a promising strategy for delaying aging and treating age-associated diseases, with rapid advancements in recent years, particularly in the development of highly efficient tools such as CRISPR-Cas9, zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs).117 The core principle of gene editing lies in programmably targeting specific DNA sequences to modify the genome, thereby repairing mutations, correcting aberrant gene expression, and restoring normal cellular function.118 For example, using CRISPR-Cas9 genome editing, researchers reduced the expression of both lamin A and the pathogenic protein progerin in a mouse model of HGPS, while preserving lamin C.16 This led to an improvement in disease phenotypes and extended lifespan by approximately 25%, although editing efficiency varied across tissues and human applications remain preclinical.16 While CRISPR-Cas9 is the most widely used platform, newer editors like base editors and prime editors offer potential advantages for aging interventions by enabling precise single-base changes or small insertions without generating double-strand breaks, thereby reducing the risk of unintended genomic rearrangements.119 2.Gene replacement and overexpression Gene replacement and overexpression Gene replacement and overexpression strategies involve delivering functional copies of genes to compensate for defective or missing alleles or to upregulate genes with therapeutic potential, thereby exerting biological effects in target cells and tissues. In the clinical realm, Luxturna (voretigene neparvovec) exemplifies the gene replacement paradigm: an AAV vector delivers a functional RPE65 coding sequence into retinal cells to restore visual function in patients with RPE65-associated inherited retinal dystrophy, demonstrating the feasibility and durability of in vivo gene delivery for human disease. While this application addresses a monogenic disorder rather than aging per se, the success of Luxturna illustrates the clinical potential of gene delivery platforms for permanent transgene expression.120 In the context of aging, preclinical studies have increasingly utilized overexpression approaches to modulate aging-associated pathways. For example, AAV-mediated overexpression of the klotho gene in mice improves multiple hallmarks of aging, enhances regenerative capacity, and can extend lifespan, providing proof of concept that therapeutic gene delivery can modulate age-associated phenotypes in vivo.121 3.Transcriptional regulation Transcriptional regulation An emerging strategy involves modulating gene expression without altering the underlying genome. CRISPR-based transcriptional modulators, CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), use catalytically inactive Cas9 (dCas9) fused to repressor or activator domains to achieve reversible and tunable gene regulation.122,123 This technique has been applied to aging models for both upregulating protective genes and downregulating senescence drivers. For example, CRISPRa-mediated activation of ARID5A has been shown to support fibroblast, cardiomyocyte, and endothelial cell function, indicating potential in cardiovascular aging.124 A key advantage of CRISPRa/i over traditional gene editing is their reversibility and tunability, which may provide a safer profile for modulating aging processes that require precise temporal control rather than permanent genetic alteration. 4.Epigenetic editing Epigenetic editing In addition to transcriptional modulation, epigenetic editing has emerged as a versatile DNA-targeted strategy that reprograms gene expression without altering nucleotide sequences. dCas9 fused to epigenetic effector domains enables locus-specific remodeling of chromatin states. For instance, dCas-DNMT3A/3L induces targeted DNA methylation to silence gene activity, whereas dCas9-TET1 promotes demethylation and transcriptional activation.125,126 Likewise, dCas9-p300 was used to elevate endogenous Gad1, illustrating disease-model applications of locus-specific epigenetic editing rather than direct geroprotective efficacy.127 Mechanistically, these platforms reshape enhancer-promoter communication and modulate chromatin accessibility at defined loci. Current evidence supports primarily localized, locus-specific remodeling, with global or durable rejuvenation of age-associated epigenomic patterns remaining under investigation. Because epigenetic changes accumulate progressively with age and are reversible, these programmable tools provide a compelling framework for precise gene regulation; however, durability, locus specificity, and potential off-target effects warrant careful evaluation, particularly for aging interventions. DNA-based interventions offer useful tools to target aging at its molecular roots; however, their application in aging poses challenges distinct from monogenic disease correction. Aging is systemic and lifelong, potentially requiring broad tissue distribution and sustained or repeated intervention. Thus, durability becomes a double-edged sword: while persistent expression may enhance efficacy, prolonged nuclease or transgene activity increases cumulative risks of off-target mutagenesis, genomic instability, and clonal expansion over decades, even if individual events are rare.128 In addition, age-associated declines in DNA repair capacity and immunosenescence may alter both editing fidelity and immune responses to viral vectors or Cas proteins, complicating safety and re-dosing strategies.129 Because aging interventions may be administered to otherwise healthy individuals, acceptable risk thresholds are substantially lower than in life-threatening genetic disorders. Therefore, clinical translation of DNA-based gerotherapeutics will require stringent temporal control, reversibility, dose optimization, and long-term genomic monitoring to balance durability with safety. RNA-based genetic strategies for aging intervention RNA-based therapies provide a reversible and tunable alternative to DNA-targeting approaches. By acting primarily at the transcript level, they avoid permanent genomic modification and allow dose adjustment or treatment cessation, features that are particularly valuable for modulating dynamic aging processes. However, their transient activity often requires repeated administration and places high demands on delivery efficiency, RNA stability, and tissue specificity. 1.siRNA siRNA Small interfering RNAs (siRNAs) are ∼21- to 23-nucleotide double-stranded RNAs that guide RNA-induced silencing complex-mediated degradation of complementary mRNAs. Their favorable specificity, transient activity, and clinical tractability make them attractive for modulating aging-associated pathways.130 For example, inclisiran, an FDA-approved siRNA targeting PCSK9, lowers low-density lipoprotein cholesterol (LDL-C) and is clinically relevant for older adults at high cardiovascular risk.131 Chemical modifications further improve stability, biodistribution, and target specificity while reducing immune activation. 2.shRNA shRNA Short hairpin RNAs (shRNAs) are vector-encoded RNA interference tools that are processed intracellularly into siRNA-like molecules, enabling more sustained gene silencing than synthetic siRNAs.130 Because shRNAs are commonly delivered by AAV or LVs, they may be useful for chronic modulation of aging-associated transcripts. However, their prolonged expression creates challenges in dose control, reversibility, and off-target toxicity, making them less flexible than chemically synthesized siRNAs for preventive aging interventions. 3.ASO ASO ASOs are single-stranded nucleic acids that bind target RNAs to induce ribonuclease H (RNase H)-mediated degradation, modulate splicing, or block translation. Their diverse mechanisms and established clinical use make them particularly suitable for age-associated diseases and inflammatory aging.132 For example, ASO-mediated targeting of the neonatal Fc receptor (FcRn) reduces IgG levels, alleviates age-associated immune hyperactivation, and delays functional decline across multiple organs.79 4.CRISPR-Cas13d CRISPR-Cas13d CRISPR-Cas13d enables programmable RNA targeting without permanent genome editing, allowing transcript degradation, splicing modulation, or RNA-level regulation. High-fidelity Cas13 variants with reduced collateral activity have improved the specificity of this approach.133 In C9orf72-associated amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) models, Cas13d-mediated RNA targeting reduces toxic repeat-associated products, illustrating its potential for age-associated neurodegenerative diseases.134 Its reversibility and RNA-level specificity also make Cas13d a useful platform for interrogating aging-associated transcriptomic networks, although direct geroprotective applications remain at an early stage. Despite their promise, RNA-based therapeutics face major translational barriers, including delivery to aging-relevant tissues such as the brain, muscle, and stem-cell niches, as well as optimization of RNA stability, immune compatibility, and redosing regimens. Long-term safety and geroprotective efficacy will require further validation in relevant preclinical models, including non-human primates. Gene delivery platforms for aging intervention Vector-assisted gene delivery represents a cornerstone technology for achieving precise and efficient nucleic acid transport in gene therapy, offering a means to safely and stably deliver therapeutic payloads to aging-associated tissues or cell types. In the context of aging intervention and related disease research, such delivery platforms provide essential protection and tissue-penetrating capabilities for nucleic acid-based drugs, broadening their clinical applicability.135 Currently, the most widely used delivery vectors include viral vectors and non-viral systems, all of which are being actively investigated for gene interventions in neurodegenerative, cardiovascular, and metabolic disorders associated with aging. 1.Viral delivery systems Viral delivery systems AAV vectors are among the most widely used platforms for in vivo gene transfer because they efficiently transduce dividing and non-dividing cells, support long-lasting expression in post-mitotic tissues, and have relatively low pathogenicity. These features make AAV particularly attractive for aging-associated gene therapy. In preclinical studies, AAV-mediated telomerase delivery ameliorated selected age-associated phenotypes in mice,136 while AAV2-driven OSK expression restored retinal function and optic nerve integrity.137 However, AAV-based strategies remain constrained by limited packaging capacity, pre-existing anti-capsid immunity, dose-dependent immune responses, rare integration events, and safety concerns associated with uncontrolled long-term transgene expression.138 Strategies such as serotype engineering, antibody decoys, transient immunosuppression, tissue-specific promoters, and regulatable expression systems may help mitigate these risks.139 Adenoviral vectors (AdVs) offer high-titer production, broad transduction capacity, and large payload size, making them useful for applications requiring transient expression or strong immunogenicity, such as vaccines and cancer immunotherapy.140 However, their immunogenicity and relatively short-lived expression limit their suitability for long-term geroprotective interventions. Despite this limitation, adenoviral vectors continue to be a valuable tool in experimental and clinical settings, particularly for applications that do not require long-term transgene expression. LVs enable stable genomic integration and durable transgene expression in both dividing and non-dividing cells, with larger payload capacity than AAV. They are useful for ex vivo engineering and experimental modulation of aging-associated genes; for example, LV-mediated KAT7 suppression extends lifespan in progeroid mice.30 Nevertheless, insertional mutagenesis risk, manufacturing complexity, and scalability challenges restrict their broader application in preventive aging interventions. Retroviral vectors (RVs) also integrate into the host genome and provide stable expression in dividing cells, but their dependence on cell division and insertional mutagenesis risk make them less suitable for most aging tissues.141 Overall, viral vectors remain central tools for aging-related gene delivery, but their clinical translation will require improved tissue targeting, controlled expression, minimized immunogenicity, and long-term safety monitoring. 2.Non-viral delivery systems Non-viral delivery systems Lipid nanoparticles (LNPs) have emerged as leading non-viral platforms for nucleic acid delivery because they can encapsulate diverse payloads, including mRNA, siRNA, and CRISPR components, while avoiding viral-vector integration risks.142 Their clinical and preclinical utility is particularly evident in liver-directed RNA delivery, but predominant hepatic tropism remains a limitation for systemic aging interventions. Emerging organ-selective strategies, such as selective organ targeting (SORT) LNPs, can redirect biodistribution toward tissues including liver, lung, and spleen, although efficient delivery to many aging-relevant tissues, such as brain, muscle, and stem-cell niches, remains challenging.143 Hydrogels provide an additional localized delivery platform, offering biocompatible and sustained release of nucleic acid payloads while limiting systemic exposure. They may be useful for focal aging-associated pathologies, such as skin degeneration, osteoarthritis, or localized tissue repair, but their role in systemic geroprotective gene therapy remains limited.144 Overall, non-viral platforms offer improved reversibility, manufacturability, and redosing potential compared with viral vectors, but future translation will require better tissue targeting, endosomal escape, payload stability, and long-term safety validation. Cell-based platforms for geroprotective intervention Genetically modified cell therapy represents an emerging, but still early-stage, platform for geroprotective intervention.145 iPSC-derived RPE cells have been explored for AMD-related cell replacement, although their connection to systemic aging intervention remains indirect and challenges persist regarding differentiation fidelity, immune compatibility, engraftment, and tumorigenic safety.146 Engineered immune-cell strategies, including CAR-T cells targeting senescence-associated antigens, have provided preclinical proof of concept for selective senescent-cell clearance and improvement of selected senescence-associated phenotypes, but translation to aging indications will require rigorous validation of target specificity, persistence, tissue distribution, and off-tissue toxicity.147 FOXO3-enhanced human mesenchymal stem cells, or senescence-resistant cells, have been reported to withstand aging-related stress and improve selected aging-related phenotypes in aged cynomolgus monkeys, providing initial primate evidence for genetically enhanced progenitor-cell approaches.148 However, their long-term durability, mechanism of action, biodistribution, and safety require further independent validation. Overall, cell-based gene platforms may complement vector- and RNA-based strategies, but their clinical translation will depend on stringent control of genetic stability, tumorigenicity, manufacturing consistency, immune compatibility, and long-term monitoring. Translational considerations and safety paradigms Effective aging interventions require balancing durable efficacy, safety, and rational target selection. DNA-based strategies (CRISPR, gene replacement) provide long-lasting effects but risk off-target mutations, immune responses, and genomic instability, while RNA-based approaches (siRNA, ASO, and Cas13) are reversible and lower genomic risk, although often requiring repeated dosing and facing delivery challenges. Delivery platforms further influence feasibility: viral vectors ensure persistent expression but are constrained by immunogenicity and payload, whereas non-viral carriers, such as LNPs, enable safer, multi-organ delivery with transient effects. Target genes should focus on aging hallmarks, including telomere maintenance (TERT), metabolic regulation (FOXO, SIRTs), and inflammatory pathways (NFKB1/NFKB2), and be validated with quantitative biomarkers (epigenetic clocks, SASP factors, functional assays) to ensure healthspan benefits. Integrating precise, controllable gene modulation with optimized delivery and biomarker-informed targets provides a feasible framework for translational geroprotective gene therapies. Barriers to clinical translation of gene therapy for aging Gene therapy for aging holds great promise due to its potential to modulate upstream biological mechanisms, rather than merely addressing the downstream symptoms of individual diseases. Preclinical studies have shown that genetic modulation of telomere maintenance, DNA damage responses, cellular senescence, and chromatin regulators can alter aging trajectories in vivo. However, translating these findings into human interventions has been challenging. This is not simply because aging does not align neatly with the disease-centric therapeutic, regulatory, and economic frameworks that underpin modern medicine but also because human aging is intrinsically heterogeneous. Genetic background, lifetime environmental exposures, and behavioral factors interact to shape variable aging trajectories across individuals and organ systems, thereby influencing treatment responsiveness and limiting the reproducibility and generalizability of preclinical findings.149 Aging is inherently progressive, multi-tissue, and probabilistic, with many pathways that slow aging overlapping with critical controls of proliferation, genome stability, and immune surveillance. Even modest perturbations of regulators, such as telomerase, epigenetic modifiers, and senescence circuits, raise concerns regarding oncogenesis, clonal hematopoiesis, and long-term tissue homeostasis. Preclinical studies using partial reprogramming or senescence-resistant cell strategies suggest that aging-associated phenotypes can be attenuated without overt tumorigenesis.150,151 These strategies highlight the importance of selectively targeting the right pathways and controlling gene modulation to avoid undesirable effects. Despite the improvements in safety profiles of current gene therapy platforms in rare diseases and oncology, age-associated interventions would require long-term assessments over decades, raising acceptable risk thresholds and increasing regulatory scrutiny. Sustained transgene expression, beneficial in monogenic disorders, poses challenges in aging, because the optimal timing, dosage, and tissue specificity remain poorly defined. Reversibility may be necessary, making precision and dynamic gene delivery critical. Strategies such as non-permanent gene modulation systems (e.g., CRISPRa/i) allow for controlled gene expression without permanent genetic alterations, thus helping mitigate oncogenic risks. Additionally, advanced gene delivery systems, like LNPs and exosome-based vectors, have shown potential for precise, localized delivery with minimal off-target effects. Technologies like SORT are being developed to target aging-affected tissues, such as muscle, liver, and brain, thereby reducing systemic exposure and enhancing clinical feasibility. These innovations will be pivotal in refining age-associated gene therapies and improving their clinical viability. Regulatory barriers further complicate the clinical translation of age-associated gene therapy. Aging is not recognized as a disease indication by major regulatory agencies, leaving no established approval routes or reimbursement frameworks. Unlike discrete diseases, aging also lacks validated surrogate endpoints that reliably predict morbidity or mortality, even as biomarkers such as epigenetic clocks, composite frailty scores, and inflammatory signatures continue to evolve. This challenge is compounded by marked inter-individual variability in aging trajectories, which makes it difficult to identify biomarkers that are both broadly generalizable and sufficiently responsive at the level of individual patients. The absence of consensus biomarkers complicates trial design, cohort stratification, and efficacy assessment, thereby amplifying financial and regulatory risk. Moreover, current manufacturing and delivery paradigms are optimized for high-need, low-volume diseases, making them economically misaligned with interventions targeting broad, relatively healthy populations. To address these challenges, researchers are increasingly pursuing multi-biomarker and multi-omics frameworks that may better capture the multidimensional and heterogeneous nature of human aging.152,153 Ethical and societal considerations further complicate the translation of age-associated gene therapy. Preventive interventions with population-level reach raise questions about equitable access, demographic impact, and distributive justice, issues that differ in scope and scale from therapeutic rescue interventions. In conclusion, the slower clinical progression of age-associated gene therapy reflects systemic, regulatory, and logistical challenges. Bridging these gaps will require parallel innovations in controllable gene delivery systems and the establishment of aging intervention assessment models. Progress in these areas will determine whether age-associated gene therapy remains at the conceptual stage or becomes clinically actionable. Conclusions and future perspectives Gene therapy provides a useful framework for modulating aging-associated mechanisms, but its future in geroprotection will depend on moving beyond single-gene, disease-specific models toward controllable network-level interventions. DNA-based editing, RNA modulation, epigenetic regulation, viral and non-viral delivery, and engineered cell platforms each offer distinct advantages, but all require careful calibration of dose, timing, tissue specificity, reversibility, and long-term safety. The next stage of the field should prioritize biomarker-guided target selection, multi-omics assessment, detectable preclinical validation in relevant models, and clinically meaningful endpoints. Integrated with pharmacological, lifestyle, and regenerative approaches, gene-based interventions may eventually become part of a precision geromedicine framework aimed at reducing age-associated dysfunction and extending healthspan. Acknowledgments This work was supported by the National Natural Science Foundation of China (82488301, 82125011, 82501882, 82330044, 32341001, 82361148130, and 82350710800), Non-Communicable Chronic Diseases-National Science and Technology Major Project (2024ZD0530400), CAS Project for Young Scientists in Basic Research (YSBR-076), and New Cornerstone Science Foundation through the XPLORER PRIZE (2021-1045). Author contributions M.J., J.Q., M.S., and G.-H.L. contributed equally to data collection and content discussion. M.J. drafted the original manuscript and prepared all figures. M.S. guided the overall logical framework of the manuscript. J.Q., M.S., and G.-H.L. participated in manuscript revision and intellectual supervision. Declaration of interests The authors declare no competing interests. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2026.102870. Contributor Information Jing Qu, Email: qujing@ioz.ac.cn. Moshi Song, Email: songmoshi@ioz.ac.cn. Guang-Hui Liu, Email: ghliu@ioz.ac.cn. Supplemental information Document S1. Table S1 Document S2. Article plus supplemental information References Associated Data Supplementary Materials Document S1. Table S1 Document S2. Article plus supplemental information